BACKGROUND: Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting. METHODS: To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D; IDS Inc.; enzyme immunoassay) were associated with risk of pancreatic cancer, we conducted a pooled analysis of nested case-control studies with 451 cases and 1,167 controls from five cohorts through 2008. Median follow-up among controls was 14.1 years in Health Professionals Follow-Up Study (HPFS), 18.3 years in Nurses' Health Study (NHS), 25.3 years in Physicians' Health Study (PHS), 12.2 years in Women's Health Initiative-Observational Study (WHI), and 14.4 years in Women's Health Study (WHS). Logistic regression was used to compare the odds of pancreatic cancer by plasma level of 25(OH)D. RESULTS: Mean plasma 25(OH)D was lower in cases versus controls (61.3 vs. 64.5 nmol/L, P = 0.005). In logistic regression models, plasma 25(OH)D was inversely associated with odds of pancreatic cancer. Participants in quintiles two through five had multivariable-adjusted ORs (95% confidence intervals) of 0.79 (0.56-1.10), 0.75 (0.53-1.06), 0.68 (0.48-0.97), and 0.67 (0.46-0.97; P(trend) = 0.03), respectively, compared with the bottom quintile. Compared with those with insufficient levels [25[OH]D, <50 nmol/L], ORs were 0.75 (0.58-0.98) for subjects with relative insufficiency [25[OH]D, 50 to <75 nmol/L] and 0.71 (0.52-0.97) for those with sufficient levels [25[OH]D, ≥ 75 nmol/L]. No increased risk was noted in subjects with 25(OH)D ≥100 nmol/L, as suggested in a prior study. In subgroup analyses, ORs for the top versus bottom quartile of 25(OH)D were 0.72 (0.48-1.08) for women, 0.73 (0.40-1.31) for men, and 0.73 (0.51-1.03) for Whites. CONCLUSIONS: Among participants in five large prospective cohorts, higher plasma levels of 25(OH)D were associated with a lower risk for pancreatic cancer. IMPACT: Low circulating 25(OH)D may predispose individuals to the development of pancreatic cancer.
BACKGROUND: Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting. METHODS: To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D; IDS Inc.; enzyme immunoassay) were associated with risk of pancreatic cancer, we conducted a pooled analysis of nested case-control studies with 451 cases and 1,167 controls from five cohorts through 2008. Median follow-up among controls was 14.1 years in Health Professionals Follow-Up Study (HPFS), 18.3 years in Nurses' Health Study (NHS), 25.3 years in Physicians' Health Study (PHS), 12.2 years in Women's Health Initiative-Observational Study (WHI), and 14.4 years in Women's Health Study (WHS). Logistic regression was used to compare the odds of pancreatic cancer by plasma level of 25(OH)D. RESULTS: Mean plasma 25(OH)D was lower in cases versus controls (61.3 vs. 64.5 nmol/L, P = 0.005). In logistic regression models, plasma 25(OH)D was inversely associated with odds of pancreatic cancer. Participants in quintiles two through five had multivariable-adjusted ORs (95% confidence intervals) of 0.79 (0.56-1.10), 0.75 (0.53-1.06), 0.68 (0.48-0.97), and 0.67 (0.46-0.97; P(trend) = 0.03), respectively, compared with the bottom quintile. Compared with those with insufficient levels [25[OH]D, <50 nmol/L], ORs were 0.75 (0.58-0.98) for subjects with relative insufficiency [25[OH]D, 50 to <75 nmol/L] and 0.71 (0.52-0.97) for those with sufficient levels [25[OH]D, ≥ 75 nmol/L]. No increased risk was noted in subjects with 25(OH)D ≥100 nmol/L, as suggested in a prior study. In subgroup analyses, ORs for the top versus bottom quartile of 25(OH)D were 0.72 (0.48-1.08) for women, 0.73 (0.40-1.31) for men, and 0.73 (0.51-1.03) for Whites. CONCLUSIONS: Among participants in five large prospective cohorts, higher plasma levels of 25(OH)D were associated with a lower risk for pancreatic cancer. IMPACT: Low circulating 25(OH)D may predispose individuals to the development of pancreatic cancer.
Authors: Rachael Z Stolzenberg-Solomon; Reinhold Vieth; Azar Azad; Pirjo Pietinen; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Res Date: 2006-10-15 Impact factor: 12.701
Authors: Reinhold Vieth; Heike Bischoff-Ferrari; Barbara J Boucher; Bess Dawson-Hughes; Cedric F Garland; Robert P Heaney; Michael F Holick; Bruce W Hollis; Christel Lamberg-Allardt; John J McGrath; Anthony W Norman; Robert Scragg; Susan J Whiting; Walter C Willett; Armin Zittermann Journal: Am J Clin Nutr Date: 2007-03 Impact factor: 7.045
Authors: Esther K Wei; Edward Giovannucci; Charles S Fuchs; Walter C Willett; Christos S Mantzoros Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: Halcyon G Skinner; Dominique S Michaud; Edward Giovannucci; Walter C Willett; Graham A Colditz; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-09 Impact factor: 4.254
Authors: Edward Giovannucci; Yan Liu; Eric B Rimm; Bruce W Hollis; Charles S Fuchs; Meir J Stampfer; Walter C Willett Journal: J Natl Cancer Inst Date: 2006-04-05 Impact factor: 13.506
Authors: Brian M Wolpin; Dominique S Michaud; Edward L Giovannucci; Eva S Schernhammer; Meir J Stampfer; JoAnn E Manson; Barbara B Cochrane; Thomas E Rohan; Jing Ma; Michael N Pollak; Charles S Fuchs Journal: Cancer Res Date: 2007-08-15 Impact factor: 12.701
Authors: Eva Schernhammer; Brian Wolpin; Nader Rifai; Barbara Cochrane; Jo Ann Manson; Jing Ma; Ed Giovannucci; Cynthia Thomson; Meir J Stampfer; Charles Fuchs Journal: Cancer Res Date: 2007-06-01 Impact factor: 12.701
Authors: María Elena Martínez; Elizabeth T Jacobs; John A Baron; James R Marshall; Tim Byers Journal: J Natl Cancer Inst Date: 2012-04-25 Impact factor: 13.506
Authors: Brian M Wolpin; Peter Kraft; Jihye Kim; Chen Yuan; Ana Babic; Ying Bao; Clary B Clish; Michael N Pollak; Laufey T Amundadottir; Alison P Klein; Rachael Z Stolzenberg-Solomon; Pari V Pandharipande; Lauren K Brais; Marisa W Welch; Kimmie Ng; Edward L Giovannucci; Howard D Sesso; JoAnn E Manson; Meir J Stampfer; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-22 Impact factor: 4.254
Authors: Marina R Piper; D Michal Freedman; Kim Robien; William Kopp; Helen Rager; Ronald L Horst; Rachael Z Stolzenberg-Solomon Journal: Am J Clin Nutr Date: 2015-04-22 Impact factor: 7.045
Authors: M Waterhouse; H A Risch; C Bosetti; K E Anderson; G M Petersen; W R Bamlet; M Cotterchio; S P Cleary; T I Ibiebele; C La Vecchia; H G Skinner; L Strayer; P M Bracci; P Maisonneuve; H B Bueno-de-Mesquita; W Zaton Ski; L Lu; H Yu; K Janik-Koncewicz; J Polesel; D Serraino; R E Neale Journal: Ann Oncol Date: 2015-05-14 Impact factor: 32.976
Authors: Ying Bao; Edward L Giovannucci; Peter Kraft; Meir J Stampfer; Shuji Ogino; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; John Michael Gaziano; Nader Rifai; Michael N Pollak; Barbara B Cochrane; Virginia Kaklamani; Jennifer H Lin; Joann E Manson; Charles S Fuchs; Brian M Wolpin Journal: J Natl Cancer Inst Date: 2012-12-14 Impact factor: 13.506
Authors: Chen Yuan; Clary B Clish; Chen Wu; Jared R Mayers; Peter Kraft; Mary K Townsend; Mingfeng Zhang; Shelley S Tworoger; Ying Bao; Zhi Rong Qian; Douglas A Rubinson; Kimmie Ng; Edward L Giovannucci; Shuji Ogino; Meir J Stampfer; John Michael Gaziano; Jing Ma; Howard D Sesso; Garnet L Anderson; Barbara B Cochrane; JoAnn E Manson; Margaret E Torrence; Alec C Kimmelman; Laufey T Amundadottir; Matthew G Vander Heiden; Charles S Fuchs; Brian M Wolpin Journal: J Natl Cancer Inst Date: 2016-01-11 Impact factor: 13.506
Authors: J M Genkinger; M Wang; R Li; D Albanes; K E Anderson; L Bernstein; P A van den Brandt; D R English; J L Freudenheim; C S Fuchs; S M Gapstur; G G Giles; R A Goldbohm; N Håkansson; P L Horn-Ross; A Koushik; J R Marshall; M L McCullough; A B Miller; K Robien; T E Rohan; C Schairer; D T Silverman; R Z Stolzenberg-Solomon; J Virtamo; W C Willett; A Wolk; R G Ziegler; S A Smith-Warner Journal: Ann Oncol Date: 2014-03-14 Impact factor: 32.976
Authors: Chen Yuan; Zhi Rong Qian; Ana Babic; Vicente Morales-Oyarvide; Douglas A Rubinson; Peter Kraft; Kimmie Ng; Ying Bao; Edward L Giovannucci; Shuji Ogino; Meir J Stampfer; John Michael Gaziano; Howard D Sesso; Julie E Buring; Barbara B Cochrane; Rowan T Chlebowski; Linda G Snetselaar; JoAnn E Manson; Charles S Fuchs; Brian M Wolpin Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544